Stopping or maintaining oral anticoagulation in patients undergoing photoselective vaporization of the prostate (SOAP) surgery for benign prostate obstruction: study protocol for a multicentre randomized controlled trial
Authors:
- Hélène CharbonneauHCHélène Charbonneau
- Marie PasquiéMPMarie Pasquié
- Benoit PeyronnetBPBenoit Peyronnet
- Aurélien DescazeaudADAurélien Descazeaud
- Nicolas Barry-DelongchampsNBNicolas Barry-Delongchamps
- Emmanuel Della NegraENEmmanuel Della Negra
- Romain MathieuRMRomain Mathieu
- Gilles KarsentyGKGilles Karsenty
- Jean-Alexandre LongJLJean-Alexandre Long
- Charles BallereauCBCharles Ballereau
- Abdel-Rahmène AzzouziAAAbdel-Rahmène Azzouzi
- Benjamin PradèreBenjamin Pradère
Open Access
- 27 December 2018
- journal article
- research article
- Published by Springer Nature in Trials
- Vol. 19 (1) , 1-8
Abstract
Lower urinary tract symptoms related to benign prostatic obstruction (BPO) are frequent in men aged > 50 years. Based on the use of innovative medical devices, a number of transurethral ablative techniques have recently been developed for the surgical treatment of BPO. In recent years, GreenLight photoselective vaporization of the prostate (PVP) has been considered as a non-inferior alternative to transurethral resection of the prostate. The GreenLight PVP is usually considered as an interesting surgical option for patients treated via oral anticoagulants (OACs) with regard to its haemostatic properties. The aim of this study was to assess the impact of maintaining OAC treatment in patients undergoing PVP. This study is a multicentre, open-label, randomized controlled trial (RCT) designed to show the non-inferiority of PVP surgery in patients with BPO treated with OACs. This study is designed to enrol 386 OAC-treated patients (treated with vitamin K antagonists and direct oral anticoagulants) who are undergoing PVP for BPO. Patients will be randomized (1:1) to either maintain or stop OAC treatment during the perioperative course. The intervention group will maintain OAC treatment until the day before surgery and resume OAC treatment the day after surgery, whereas the control group will stop OAC treatment (with or without low-molecular-weight heparin bridging therapy) according to the anaesthesia guidelines. The primary outcome of interest to be assessed is the 30-day complications rate according to the Clavien-Dindo classification. The secondary endpoint will examine the 30-day rate of haemorrhagic and thrombotic events. This study will provide 80% power to show non-inferiority, defined as not worse than a 10% (non-inferiority margin) inferior change in the proportion of patients with good outcomes (Clavien-Dindo score < 2), using two-tailed 95% confidence intervals. This first multicentre RCT in the field is underway to evaluate the safety and efficacy of PVP in patients with ongoing OAC therapy. The study results could influence the perioperative management of OACs in BPO surgery with a high level of evidence. ClinicalTrials.gov, NCT03297281 . Registered on 29 September 2017.Keywords
Funding Information
- Boston Scientific Corporation
This publication has 26 references indexed in Scilit:
- Photoselective Vaporisation of the Prostate Using 80-W and 120-W Laser Versus Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia: A Systematic Review with Meta-Analysis from 2002 to 2012European Urology, 2012
- Photoselective vaporization of the prostate using the 180W lithium triborate laserAnz Journal of Surgery, 2012
- 180-W XPS GreenLight Laser Therapy for Benign Prostate Hyperplasia: Early Safety, Efficacy, and Perioperative Outcome After 201 ProceduresEuropean Urology, 2012
- Laser Treatment of Benign Prostatic Obstruction: Basics and Physical DifferencesEuropean Urology, 2012
- Meta-analysis of Functional Outcomes and Complications Following Transurethral Procedures for Lower Urinary Tract Symptoms Resulting from Benign Prostatic EnlargementEuropean Urology, 2010
- The Clavien-Dindo Classification of Surgical ComplicationsAnnals of Surgery, 2009
- GreenLight Laser Vaporization of the Prostate: Single-Center Experience and Long-Term Results After 500 ProceduresEuropean Urology, 2008
- Points to consider on switching between superiority and non‐inferiorityBritish Journal of Clinical Pharmacology, 2001
- Potassium-titanyl-phosphate laser vaporization of the prostate: A comparative functional and pathologic study in caninesUrology, 1996
- A comparison of the Two One-Sided Tests Procedure and the Power Approach for assessing the equivalence of average bioavailabilityJournal of Pharmacokinetics and Biopharmaceutics, 1987